Dr. Jianjun ZOU, General Manager and CEO of Junshi Biosciences, said, “As of now, toripalimab has been approved for marketing in over 30 countries and regions across three continents worldwide. With ...

mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment. As ...

That brings us to Summit Therapeutics (NASDAQ: SMMT), a drugmaker whose shares have skyrocketed by almost 700% since the year ...

Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...

It is Transgene's second most advanced neoantigen immunotherapy programme after TG4050 for head and neck cancer, which is in ...

Researchers have discovered that combining immunotherapy and chemotherapy can overcome treatment resistance in a subset of ...

*仅供医学专业人士阅读参考把肿瘤微环境内因抗原慢性刺激转入耗竭状态的CD8+T细胞“叫醒”，让它们重新活化为效应CD8+T细胞，是PD-1/L1抑制剂为代表的现有免疫治疗起效的关键，但实话实说，激活处在耗竭状态的CD8+T细胞，在奇点糕眼里总觉得有点 ...

When I was diagnosed with lung cancer, I didn’t want to receive chemotherapy, especially when I was a good candidate for ...

*仅供医学专业人士阅读参考在目前已经获批的各种免疫联合治疗方案里，PD-1/L1抑制剂和CTLA-4抑制剂组成的“双免疫方案”，经常给奇点糕一种双刃剑的感觉，一方面它们确实取得了不少关键临床研究的成功，对非小细胞肺癌（NSCLC）、肝癌等常见实体瘤有 ...

Leads Biolabs’ LBL-024 receives Breakthrough Therapy Designation from China NMPA to treat extrapulmonary neuroendocrine carcinoma: Nanjing, China Thursday, October 10, 2024, 10: ...

Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the ...